Lilly Pays $1.5B Cash for Private Biotech Calytrix Bio
LLY sits 71% above its 52-week low of $850.51.
Summary
Lilly agreed to buy privately held Calytrix Bio for $1.5 billion in cash, adding another bolt-on to a pipeline buildout that already includes the Merida Biosciences deal announced in late August. Calytrix shareholders receive an upfront cash payment plus clinical and regulatory milestone payments, and the company's lead biparatopic antibody targets mutant calreticulin-driven essential thrombocythemia and myelofibrosis. The price is small next to Lilly's scale and its recent $4.2 billion of acquired IPR&D charges from the AtaiBeckley and Curevo deals, so this is a modest, incremental spend rather than a thesis-changing bet. Lilly is trading near its 52-week high after a 39% revenue jump in Q3, and management has been steadily buying pipeline assets with cash flow from Mounjaro and Zepbound.
Updated with a Benzinga report · What changed
Updates
· Benzinga — Calytrix shareholders receive an upfront cash payment plus clinical and regulatory milestone payments; Calytrix's lead biparatopic antibody targets mutant calreticulin-driven essential thrombocythemia and myelofibrosis.
At the time of this announcement, LLY was trading at $1,455.36 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.4T. The 52-week trading range was $850.51 to $1,460.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.